Clinical trial · Interventional
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells
Gene Expression Analysis in Cutaneous T-Cell Lymphoma
NCT00020072CI-TRIAL-00017703completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous T-cell lymphoma. PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size OR * Immunologically proven Sezary syndrome with all of the following: * Erythroderma * Lymphadenopathy * T-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry OR * CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells PATIENT CHARACTERISTICS: Age: * 18 to 85 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant or nursing * HIV-1 and HTLV-1 negative * No prior intravenous drug use PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 2 months since prior systemic chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 2 months since prior electron beam radiotherapy Surgery: * Not specified Other: * At least 2 weeks since prior topical therapy * At least 2 months since prior photopheresis * At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB) therapy
References
Publications (1)
- RESULTHwang ST, Fitzhugh DJ. Aberrant expression of adhesion molecules by Sezary cells: functional consequences under physiologic shear stress conditions. J Invest Dermatol. 2001 Mar;116(3):466-70. doi: 10.1046/j.1523-1747.2001.01282.x. PMID 11231324